Introduction Human papillomavirus (HPV) infection, which poses significant disease burden,
is decreasing following implementation of vaccination programs. Synthesized evidence on …

Objectives Despite their use, differences in human papillomavirus (HPV) vaccine efficacies
remain uncertain. This study assesses efficacy differences among bivalent, quadrivalent …

Prophylactic human papillomavirus (HPV) vaccine represents a revolutionary step forward in
preventing HPV-related cancers, especially cervical carcinoma. Alongside appropriate …

Prophylactic human papillomavirus (HPV) vaccination programs constitute major public
health initiatives worldwide. We assessed the global effect of quadrivalent HPV (4vHPV) …

Persistent oncogenic human papillomavirus (HPV) is the cause of cervical cancer, as well as
cancers of the anus, penis, vulva, vagina and oropharynx. There is good evidence that …

Background Human papillomavirus (HPV) vaccines were first licensed as a three-dose
series. Two doses are now widely recommended in some age groups; there are data …

Background Uptake of human papillomavirus (HPV) vaccine remains low in many countries,
although the bivalent and quadrivalent HPV vaccines given as a three‐dose schedule are …

HPV-related diseases represent a major cause of morbidity and mortality, although effective
HPV vaccines are available, potentially allowing for the elimination of these malignancies …

Background The quadrivalent human papillomavirus (HPV) vaccine was shown to prevent
infections and lesions related to HPV6, 11, 16, and 18 in a randomised, placebo-controlled …

Cervical cancer incidence and mortality have decreased in high-income countries, but low-
and middle-income countries continue to bear a significant burden from the disease. Human …